Lido Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lido Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,719	Closed	-$323K	–	2145
2026 Q1	$323K	Buy	+5,719	New	+$333K	﹤0.01%	1524

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Lido Advisors's BMRN Position: Q2 2026 in Review

Lido Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 5,719 shares — an estimated $323K sold.

Lido Advisors first reported a position in BMRN in Q1 2026 and held it in 1 quarter. The position peaked at $323K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Lido Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Lido Advisors sold 5,719 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $323K.
Lido Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Lido Advisors's BioMarin Pharmaceuticals position peaked at $323K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.